-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
February 5, 2021 // -- A recent article published in the international magazine Journal of the National Cancer Institute entitled "Associations of aspirin and non-aspirin non-steroidal anti-igny drugs with Scientists from institutions such as the Siddasi Nai Medical Center in the United States have found that long-term aspirin use prior to diagnosis of colorectal cancer (CRC) may be directly associated with lower colorectal cancer mortality, according to the study.
Photo Source: Wikipedia/CC BY-SA 3.0 Researchers point out that the use of aspirin before diagnosis may help reduce the risk and mortality of colorectal cancer in the general population by limiting the metastatic spread of pre-diagnosis colorectal cancer, and preventing far-end metastasis of cancer cells also reduces the number of deaths from colorectal cancer. in the
study, researcher Peter T. Campbell and others analyzed data from the American Cancer Society's Cancer Prevention Research Program II (CPS-II) Nutritional Cohort study of men and women who did not develop cancer during the baseline period (1992/1993) and were diagnosed with colorectal cancer during follow-up in 2015, and by the end of 2016, researchers had completed their mortality survey.
The findings in this paper are important because colorectal cancer patients often look for lifestyle recommendations to improve their disease prognosis; the researchers analyzed the association between nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer-specific mortality rates in colorectal cancer survivors before and after diagnosis.
researchers say that while more evidence is needed to confirm the link, preferably from randomized controlled trials.
This study is also expected to provide an important resource to help guide clinicians and colorectal cancer survivors on the potential benefits and harms of taking aspirin and non-aspirin nonsteroidal anti-inflammatory drugs.
original source: Jane C Figueiredo, PhD, Eric J Jacobs, PhD, Christina C Newton, MSPH, et al. Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis, JNCI:Journal of the National Cancer Institute, djab008, doi:10.1093/jnci/djab008